Wilmington Savings Fund Society FSB Acquires Shares of 3,033 Natera, Inc. (NASDAQ:NTRA)

Wilmington Savings Fund Society FSB bought a new position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund bought 3,033 shares of the medical research company's stock, valued at approximately $385,000.

A number of other large investors have also modified their holdings of NTRA. Sanctuary Advisors LLC increased its holdings in shares of Natera by 113.1% in the 3rd quarter. Sanctuary Advisors LLC now owns 7,486 shares of the medical research company's stock valued at $950,000 after purchasing an additional 3,973 shares in the last quarter. Coldstream Capital Management Inc. acquired a new position in Natera during the third quarter worth about $305,000. Geode Capital Management LLC increased its holdings in Natera by 7.4% in the third quarter. Geode Capital Management LLC now owns 2,090,480 shares of the medical research company's stock valued at $265,747,000 after buying an additional 143,825 shares in the last quarter. M&T Bank Corp lifted its position in shares of Natera by 7.9% during the 3rd quarter. M&T Bank Corp now owns 5,513 shares of the medical research company's stock valued at $699,000 after acquiring an additional 405 shares during the period. Finally, Gordian Capital Singapore Pte Ltd boosted its stake in shares of Natera by 211.5% during the 3rd quarter. Gordian Capital Singapore Pte Ltd now owns 8,193 shares of the medical research company's stock worth $1,040,000 after acquiring an additional 5,563 shares in the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Natera

In related news, Director Roelof Botha sold 87,473 shares of the stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $169.12, for a total transaction of $14,793,433.76. Following the completion of the sale, the director now owns 1,224,787 shares of the company's stock, valued at approximately $207,135,977.44. This represents a 6.67 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jonathan Sheena sold 2,700 shares of the firm's stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $127.57, for a total transaction of $344,439.00. Following the completion of the transaction, the insider now owns 284,741 shares in the company, valued at $36,324,409.37. The trade was a 0.94 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 132,963 shares of company stock worth $21,250,107 in the last quarter. 7.60% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Robert W. Baird lifted their price objective on Natera from $120.00 to $160.00 and gave the stock an "outperform" rating in a report on Wednesday, November 13th. JPMorgan Chase & Co. lifted their price target on Natera from $160.00 to $200.00 and gave the stock an "overweight" rating in a research note on Friday. Sanford C. Bernstein increased their price objective on shares of Natera from $125.00 to $135.00 and gave the company an "outperform" rating in a research note on Wednesday, October 30th. StockNews.com cut shares of Natera from a "hold" rating to a "sell" rating in a research report on Thursday, November 14th. Finally, Leerink Partners increased their price target on shares of Natera from $140.00 to $150.00 and gave the company an "outperform" rating in a research report on Thursday, October 17th. One analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat.com, Natera presently has an average rating of "Moderate Buy" and an average target price of $152.67.

Natera Trading Down 1.5 %

NASDAQ NTRA traded down $2.59 during trading hours on Tuesday, hitting $168.21. 1,171,884 shares of the company's stock were exchanged, compared to its average volume of 1,330,023. The business's 50 day moving average is $144.87 and its 200-day moving average is $125.09. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. Natera, Inc. has a 12-month low of $57.22 and a 12-month high of $175.63. The firm has a market capitalization of $22.21 billion, a P/E ratio of -95.57 and a beta of 1.63.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.31. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The business had revenue of $439.80 million for the quarter, compared to analyst estimates of $361.43 million. During the same period in the prior year, the firm posted ($0.95) EPS. The company's revenue was up 63.9% on a year-over-year basis. As a group, analysts anticipate that Natera, Inc. will post -1.61 EPS for the current fiscal year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.